Adipose tissue in obesity and obstructive sleep apnoea
MR Bonsignore, WT McNicholas… - European …, 2012 - Eur Respiratory Soc
European Respiratory Journal, 2012•Eur Respiratory Soc
A European Respiratory Society research seminar on “Metabolic alterations in obstructive
sleep apnoea (OSA)” was jointly organised in October 2009 together with two EU COST
actions (Cardiovascular risk in the obstructive sleep apnoea syndrome, action B26, and
Adipose tissue and the metabolic syndrome, action BM0602) in order to discuss the
interactions between obesity and OSA. Such interactions can be particularly significant in
the pathogenesis of metabolic abnormalities and in increased cardiovascular risk in OSA …
sleep apnoea (OSA)” was jointly organised in October 2009 together with two EU COST
actions (Cardiovascular risk in the obstructive sleep apnoea syndrome, action B26, and
Adipose tissue and the metabolic syndrome, action BM0602) in order to discuss the
interactions between obesity and OSA. Such interactions can be particularly significant in
the pathogenesis of metabolic abnormalities and in increased cardiovascular risk in OSA …
A European Respiratory Society research seminar on “Metabolic alterations in obstructive sleep apnoea (OSA)” was jointly organised in October 2009 together with two EU COST actions (Cardiovascular risk in the obstructive sleep apnoea syndrome, action B26, and Adipose tissue and the metabolic syndrome, action BM0602) in order to discuss the interactions between obesity and OSA.
Such interactions can be particularly significant in the pathogenesis of metabolic abnormalities and in increased cardiovascular risk in OSA patients. However, studying the respective role of OSA and obesity is difficult in patients, making it necessary to refer to animal models or in vitro systems. Since most OSA patients are obese, their management requires a multidisciplinary approach.
This review summarises some aspects of the pathophysiology and treatment of obesity, and the possible effects of sleep loss on metabolism. OSA-associated metabolic dysfunction (insulin resistance, liver dysfunction and atherogenic dyslipidaemia) is discussed from the perspective of both obesity and OSA in adults and children.
Finally, the effects of treatment for obesity or OSA, or both, on cardio-metabolic variables are summarised. Further interdisciplinary research is needed in order to develop new comprehensive treatment approaches aimed at reducing sleep disordered breathing, obesity and cardiovascular risk.
European Respiratory Society以上显示的是最相近的搜索结果。 查看全部搜索结果